Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 65,179,000 | 45,043,000 | 34,124,000 | 28,541,400 | 28,318,400 |
| Cost of Goods | 11,052,000 | 8,418,000 | 7,082,000 | 6,629,800 | 7,312,800 |
| Gross Profit | 54,127,000 | 36,625,000 | 27,042,000 | 21,911,600 | 21,005,600 |
| Operating Expenses | 27,825,000 | 23,726,000 | 20,585,000 | 14,785,100 | 14,649,300 |
| Operating Income | 26,302,000 | 12,899,000 | 6,457,000 | 7,127,301 | 6,357,102 |
| Other Income | -571,000 | -219,000 | 97,000 | -320,901 | -201,602 |
| Pre-tax Income | 25,731,000 | 12,680,000 | 6,554,000 | 6,806,400 | 6,155,500 |
| Income Tax | 5,091,000 | 2,090,000 | 1,314,000 | 561,600 | 573,800 |
| Net Income Continuous | 20,640,000 | 10,590,000 | 5,240,000 | 6,244,800 | 5,581,700 |
| Net Income | $20,640,000 | $10,590,000 | $5,240,000 | $6,244,800 | $5,581,700 |
| EPS Basic Total Ops | 23.00 | 11.76 | 5.82 | 6.93 | 6.15 |
| EPS Basic Continuous Ops | 23.00 | 11.76 | 5.82 | 6.93 | 6.15 |
| EPS Diluted Total Ops | 22.95 | 11.71 | 5.80 | 6.90 | 6.12 |
| EPS Diluted Continuous Ops | 22.95 | 11.71 | 5.80 | 6.90 | 6.12 |
| EPS Diluted Before Non-Recurring Items | 24.21 | 12.99 | 6.32 | 7.94 | 8.16 |
| EBITDA(a) | $28,299,000 | $14,666,000 | $7,984,000 | $8,649,801 | $7,904,702 |